Till now, the serological response of HBeAg seroclearance, as well as virological and biochemical responses, was considered an important endpoint of NA treatment because HBeAg positivity has been identified as a risk factor for HCC in both treatment-naïve patients and those treated with IFN- α in previous studies. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.